CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 125,831	$ 88,980
Short-term marketable securities	292,700	259,586
Accounts receivable, net of allowances of $888 and $992 at March 31, 2018 and December 31, 2017, respectively	1,973	2,253
Receivables from collaborative arrangements	2,845	7,109
Prepaid taxes	926	291
Other prepaid and current assets	5,326	3,700
Inventories	17,217	16,830
Total current assets	446,818	378,749
Property and equipment, net	10,329	10,157
Long-term marketable securities	16,999	41,587
Tax receivable	3,324	8,191
Restricted cash	833	833
Other assets	1,805	1,883
Total assets	480,108	441,400
Current liabilities:
Accounts payable	5,085	5,924
Accrued personnel-related expenses	21,989	24,136
Accrued clinical and development expenses	16,435	20,657
Other accrued liabilities	11,508	11,710
Deferred revenue	50,162	125
Total current liabilities	105,179	62,552
Convertible senior notes, net	224,014	223,746
Deferred rent	5,772	3,668
Long-term deferred revenue	45,651	1,436
Other long-term liabilities	36,085	34,820
Commitments and contingencies
Shareholders' equity
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 54,798 and 54,381 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	1	1
Additional paid-in capital	925,968	913,650
Accumulated other comprehensive loss	(854)	(733)
Accumulated deficit	(861,708)	(797,740)
Total shareholders' equity	63,407	115,178
Total liabilities and shareholders' equity	$ 480,108	$ 441,400